TCR2 Therapeutics Plans to Raise $80 Million in IPO

Trending News 🌥️

TCR2 ($NASDAQ:TCRR) Therapeutics is a clinical-stage immuno-oncology company that is developing T-cell therapies for the treatment of cancer. The company plans to raise $80 million in an initial public offering, barely a year after it raised $125 million to advance its two T-cell therapies. Both of these product candidates are in clinical trials, and the company is hopeful that they will be able to show efficacy in the treatment of cancer. If successful, these products could revolutionize the treatment of cancer and help to improve the lives of patients. The company plans to use the proceeds from the IPO to fund the continued development of its product candidates, as well as for general corporate purposes. This is a risky investment, as the company has yet to bring a product to market.

However, the potential rewards could be huge if the company’s products are successful.

Price History

TCR2 Therapeutics plans to raise $80 million in an initial public offering, according to a filing with the Securities and Exchange Commission. At the time of writing, news sentiment around TCR2 Therapeutics’ IPO was mostly mixed. On Monday, the stock opened at $1.4 and closed at $1.4, down 2.1% from its last closing price of $1.4.

Despite the mixed sentiment, TCR2 Therapeutics believes that there is strong demand for its shares. The company plans to use the proceeds from the IPO to fund clinical trials, research and development, and working capital.

VI Analysis

The company’s platform uses a proprietary technology to genetically engineer T cells to express chimeric antigen receptors (CARs) and T cell receptors (TCRs). These CARs and TCRs enable the T cells to target and kill cancer cells. The company’s products are in clinical trials for the treatment of solid tumors and leukemia. The company’s fundamentals reflect its long term potential. The company’s platform has the potential to treat a wide range of cancers with a high degree of efficacy. The company’s products are in clinical trials and have shown promising results.

However, the company is still in the early stages of development and faces significant risks. The company’s stock is a medium risk investment in terms of financial and business aspects. The company has a high debt-to-equity ratio and is not profitable. The company’s products are in clinical trials and have not yet been approved for commercial use. The company faces significant risks, but also has significant potential rewards.

VI Peers

The company’s lead program is Tigatuzumab, which is in Phase II clinical trials for the treatment of solid tumors. TCR2 is also developing a pipeline of other T cell therapies with the potential to treat a range of cancers. TCR2’s main competitors are Brainstorm Cell Therapeutics Inc, Iovance Biotherapeutics Inc, and Immatics NV. These companies are also developing T cell therapies for the treatment of cancer.

– Brainstorm Cell Therapeutics Inc ($NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc is a biotechnology company that develops and commercializes adult stem cell therapies for neurodegenerative diseases. The company has a market cap of 59.84M and a ROE of -137.41%. Brainstorm Cell Therapeutics Inc was founded in 2004 and is headquartered in New York, New York.

– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of cancer immunotherapy products based on tumor-infiltrating lymphocytes (TIL). The company’s product candidates include LN-144, LN-145, LN-168, and LN-169. LN-144 is in Phase II clinical trials for the treatment of metastatic melanoma; LN-145 in Phase I/II clinical trials for the treatment of cervical, head and neck, and non-small cell lung cancers; LN-168 in Phase I/II clinical trials for the treatment of ovarian and gastric cancers; and LN-169 in Phase I/II clinical trials for the treatment of bladder cancer. Iovance Biotherapeutics was founded by Philip D. Gregory and Maria Fardis on October 3, 2011 and is headquartered in San Carlos, CA.

– Immatics NV ($NASDAQ:IMTX)

Immatics NV, a clinical-stage biopharmaceutical company, focuses on the development of T cell-based immunotherapies for the treatment of cancer. The company’s product candidates include IMA901 that is in Phase II clinical trials for the treatment of solid tumors, as well as in Phase I/II trials for the treatment of acute myeloid leukemia and multiple myeloma; IMA950, which is in Phase I clinical trial for the treatment of pancreatic cancer; and IMA960, a preclinical stage product candidate for the treatment of glioblastoma. Immatics NV was founded in 1999 and is headquartered in Martinsried, Germany.

Summary

Investors interested in TCR2 Therapeutics may want to consider the company’s upcoming IPO. While news sentiment surrounding the company is mixed, the company plans to raise $80 million in the offering, which could provide a boost to its share price. TCR2 Therapeutics is a clinical-stage immuno-oncology company developing novel T cell therapies for the treatment of cancer.